Intermittent infusion hemodiafiltration is associated with improved survival compared to hemodialysis
Renal Replacement Therapy - 2024
Tóm tắt
Approximately 16.4% of patients on hemodialysis (HD) in Japan are treated with intermittent infusion hemodiafiltration (I-HDF). However, large-scale data on clinical outcomes with this modality are lacking. This study aimed to compare the outcomes of I-HDF with those of conventional HD. A cohort study was conducted using the Japanese Society for Dialysis Therapy Renal Data Registry database from December 31, 2017 to December 31, 2019. The subjects were 210,574 patients on maintenance HD. The exposure of interest was I-HDF treatment versus conventional HD. The I-HDF group was divided into two subgroups based on substitution: low-volume (< 1.2 L per session) and high-volume (≥ 1.2 L per session). Outcomes included 2-year all-cause and cardiovascular mortality. The data were analyzed using Cox regression models after adjusting for potential confounders. I-HDF was associated with improved all-cause mortality compared to HD (hazard ratio: 0.94, 95% confidence interval: 0.90–0.99) after adjusting for all covariates. However, there was no significant difference in cardiovascular mortality between the two groups. In patients treated with I-HDF, the high-volume I-HDF group had improved all-cause and cardiovascular mortality compared to low-volume I-HDF or HD groups. Propensity score matching analysis revealed that the high-volume I-HDF group had better survival rates than the HD group. This observational study suggests that I-HDF, especially with high- volumes substitution, may improve all-cause and cardiovascular mortality. However, to establish a causal relationship and further evaluate the efficacy of I-HDF in improving outcomes and reducing cardiovascular events in patients on dialysis, randomized controlled trials are warranted. Trial registration UMIN000018641.
Từ khóa
Tài liệu tham khảo
Rosner MH, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P, Blankestijn PJ, Cozzolino M, Juillard L, Kashani K, Kaushik M, Kawanishi H, Massy Z, Sirich TL, Zuo L, Ronco C. Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol. 2021;16(12):1918–28.
Japanese Society for Dialysis Therapy. https://www.jsdt.or.jp/dialysis/2227.html.
Mineshima M, Eguchi K. Development of intermittent infusion hemodiafiltration using UltraPure dialysis fluid with an automated dialysis machine. Blood Purif. 2013;35(Suppl 1):55–8.
Mineshima M, Eguchi K. Validity of intermittent infusion hemodiafiltration. Blood Purif. 2019;48(Suppl 1):7–10.
Koda Y, Aoike I. Prevention of intradialytic hypotension with intermittent back-filtrate infusion haemodiafiltration: insights into the underlying mechanism. Blood Purif. 2019;48(Suppl 1):1–6.
Koda Y, Aoike I, Hasegawa S, Osawa Y, Nakagawa Y, Iwabuchi F, Iwahashi C, Sugimoto T, Kikutani T. Feasibility of intermittent back-filtrate infusion hemodiafiltration to reduce intradialytic hypotension in patients with cardiovascular instability: a pilot study. Clin Exp Nephrol. 2017;21(2):324–32.
Mineshima M, Eguchi K, Shishido K, Takahashi S, Kubo T, Kawaguchi H, Shitomi K, Shibagaki K, Suga K, Nagao H, Takada M, Taoka M, Sato T. Clinical effectiveness of intermittent infusion hemodiafiltration using Backfiltration of UltraPure dialysis fluid compared with predilution on-line hemodiafiltration. Contrib Nephrol. 2017;189:24–9.
Mineshima M, Takahashi S, Tomo T, Kawanishi H, Kawaguchi H, Minakuchi J, Nakanishi T, Sato T, Nitta K, Tsuchiya K, Masakane I, Itami N. A clinical significance of intermittent infusion hemodiafiltration using backfiltration of ultrapure dialysis fluid compared to hemodialysis: a multicenter randomized controlled crossover trial. Blood Purif. 2019;48(4):368–81.
Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Dialyzer classification and mortality in hemodialysis patients: a 3-year nationwide cohort study. Front Med (Lausanne). 2021;8:740461.
Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Dialyzer surface area is a significant predictor of mortality in patients on hemodialysis: a 3-year nationwide cohort study. Sci Rep. 2021;11(1):20616.
Hanafusa N, Abe M, Joki N, Ogawa T, Kanda E, Kikuchi K, Goto S, Taniguchi M, Nakai S, Naganuma T, Hasegawa T, Hoshino J, Miura K, Wada A, Takemoto Y. Annual dialysis data report 2019, JSDT renal data registry. Ren Replace Ther. 2023;9(1):47.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4(5):914–20.
Henderson LW. Symptomatic intradialytic hypotension and mortality: an opinionated review. Semin Dial. 2012;25(3):320–5.
Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66(3):1212–20.
Eiki K, Otake T. Factors affecting intermittent infusion hemodiafiltration. Blood Purif. 2019;48(Suppl 1):17–21.
Abe M, Masakane I, Wada A, Nakai S, Kanda E, Nitta K, Nakamoto H. High-performance dialyzers and mortality in maintenance hemodialysis patients. Sci Rep. 2021;11(1):12272.
Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. Clin Kidney J. 2022;15(3):473–83.
Nitta K, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, Goto S, Wada A, Hamano T, Hoshino J, Joki N, Abe M, Yamamoto K, Nakamoto H. Annual dialysis data report 2017, JSDT renal data registry. Ren Replace Ther. 2019;5(1):53.
Kikuchi K, Hamano T, Wada A, Nakai S, Masakane I. Predilution online hemodiafiltration is associated with improved survival compared with hemodialysis. Kidney Int. 2019;95(4):929–38.